Study #2024-1019
SWOG: Study S2213 a phase III, randomized study of Daratumumab, Cyclophosphamide, Bortezomib and Dexamethasone (DaraVCD) Induction followed by Autologous Stem Cell Transplant or Dara-VCD consolidation and Daratumumab maintenance in patients with newly diagnosed AL Amyloidosis
MD Anderson Study Status
Enrolling
Treatment Agent
Bortezomib, Cyclophosphamide, Daratumumab and Hyaluronidase-fihj, Dexamethasone, Melphalan
Description
This phase III trial compares the effect of adding a stem cell transplant with melphalan after completing chemotherapy with daratumumab, cyclophosphamide, bortezomib and dexamethasone (Dara-VCD) versus chemotherapy with Dara-VCD alone for treating patients with newly diagnosed amyloid light chain (AL) amyloidosis. Melphalan is a chemotherapy given prior to a stem cell transplant. Giving chemotherapy before a peripheral blood stem cell transplant helps kill cancer cells in the body and helps make room in the patient's bone marrow for new blood-forming cells (stem cells) to grow. The stem cells are then returned to the patients to replace the blood forming cells that were destroyed by the chemotherapy. Daratumumab is in a class of medications called monoclonal antibodies. It binds to a protein called CD38, which is found on some types of immune cells and cancer cells, including myeloma cells. Daratumumab may block CD38 and help the immune system kill cancer cells. Chemotherapy drugs, such as cyclophosphamide and bortezomib, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Dexamethasone is in a class of medications called corticosteroids. It is used to lower the body's immune response to help stop the growth of cancer cells. Giving a stem cell transplant with melphalan after Dara-VCD may kill more cancer cells in patients with newly diagnosed AL amyloidosis.
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Disease:
AL Amyloidosis
Study phase:
Phase III
Physician name:
Jing Ye
Department:
Lymphoma/Myeloma
For general questions about clinical trials:
1-877-632-6789
Help #EndCancer
Give Now
Donate Blood
Our patients depend on blood and platelet donations.
Shop UT MD Anderson
Show your support for our mission through branded merchandise.?